269 related articles for article (PubMed ID: 35701666)
1. Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas and meningiomas.
Ferreyra Vega S; Wenger A; Kling T; Olsson Bontell T; Jakola AS; Carén H
Mod Pathol; 2022 Nov; 35(11):1551-1561. PubMed ID: 35701666
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas.
Ferreyra Vega S; Olsson Bontell T; Kling T; Jakola AS; Carén H
Acta Neuropathol Commun; 2023 Feb; 11(1):23. PubMed ID: 36739454
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
4. Spatial concordance of DNA methylation classification in diffuse glioma.
Verburg N; Barthel FP; Anderson KJ; Johnson KC; Koopman T; Yaqub MM; Hoekstra OS; Lammertsma AA; Barkhof F; Pouwels PJW; Reijneveld JC; Rozemuller AJM; Beliën JAM; Boellaard R; Taylor MD; Das S; Costello JF; Vandertop WP; Wesseling P; de Witt Hamer PC; Verhaak RGW
Neuro Oncol; 2021 Dec; 23(12):2054-2065. PubMed ID: 34049406
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
7. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Weller M; Reifenberger G
Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
[TBL] [Abstract][Full Text] [Related]
8. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
Malzkorn B; Reifenberger G
Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
[TBL] [Abstract][Full Text] [Related]
9. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases.
Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R
Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367
[TBL] [Abstract][Full Text] [Related]
10. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
Sonoda Y
Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
[TBL] [Abstract][Full Text] [Related]
13. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
14. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
15. Astrocytoma (CNS WHO grade 4), IDH-mutant with co-occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A.
Leske H; Blakstad H; Lund-Iversen M; Skovholt EK; Niehusmann P; Ramm-Pettersen JT; Skogen K; Kongelf G; Sprauten M; Magelssen H; Brandal P
Neuropathology; 2023 Oct; 43(5):385-390. PubMed ID: 36754566
[TBL] [Abstract][Full Text] [Related]
16. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
[TBL] [Abstract][Full Text] [Related]
17. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
18. Overview of DNA methylation in adult diffuse gliomas.
Aoki K; Natsume A
Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
[TBL] [Abstract][Full Text] [Related]
19. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
[TBL] [Abstract][Full Text] [Related]
20. Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
Kim M; Kim S; Park YW; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
J Neurooncol; 2022 Sep; 159(3):695-703. PubMed ID: 35988090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
